POLISCOPE
Back to bills
Part ofHealthcare →

The civic record

Read. Follow. Verify.
SB 2370NORTH DAKOTASession 69State BillSigned into law
Enacted

North Dakota Orders Interim Legislative Study on Prescription Drug Transparency and Discount Programs

Original title: AN ACT to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.

Last action · June 11, 2025: Filed with Secretary Of State 05/02Sponsors: Sean Cleary and 3 others

Bill progressHistory & official text ↓
Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Does

North Dakota lawmakers direct a study during the 2025-2026 interim to examine potential reporting requirements for entities participating in the under 42 U.S.C. 256b.

Why it matters

The study lays the groundwork for potential future state regulations and reporting mandates affecting healthcare facilities, pharmacies, and drug manufacturers operating in North Dakota.

Who It Affects

Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.

Directly affected

health care facilities

Participating facilities may become subject to new mandatory data reporting requirements and enforcement mechanisms.

Directly affected

contract pharmacies

Pharmacies participating in federal discount programs face potential state-level reporting mandates.

Directly affected

drug manufacturers

Manufacturers could be required to submit transparency data regarding drug distribution and pricing under future state rules.

Directly affected

health insurers

Insurers are included among the entities evaluated for mandatory data reporting and stakeholder consultation.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What is the main goal of Senate Bill 2370?
The bill directs an interim legislative study to examine prescription drug transparency reporting under the and determine how data can be used to benefit state patients.
Who will be consulted during the legislative study?
The study must include input from professional associations representing hospitals, pharmacies, , and rural health, as well as pharmaceutical manufacturers, the insurance department, the department of health and human services, and the state board of pharmacy.
What happens after the study is completed?
The must report its findings and recommendations, along with any necessary legislation, to the seventieth legislative assembly.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Follow the record

Votes, people, money & the original source

Where This Stands

Current status: Signed into law.

Procedural history

29 actions
  1. Jun 11, 2025
    Filed with Secretary Of State 05/02
  2. May 2, 2025SenateEnrolled
    Signed by Governor 05/02
  3. May 1, 2025SenateEnrolled
    Sent to Governor
  4. May 1, 2025Senate
    Signed by President
  5. May 1, 2025House
    Signed by Speaker
  6. Apr 28, 2025HouseFloor
    Second reading, passed as amended, yeas 77 nays 12
Show 23 earlier actions
  1. Apr 28, 2025HouseCommittee
    Conference committee report adopted
  2. Apr 25, 2025HouseCommittee
    Reported back from conference committee, in place of, placed on calendar
  3. Apr 25, 2025SenateFloor
    Second reading, passed, yeas 40 nays 5
  4. Apr 25, 2025SenateCommittee
    Conference committee report adopted
  5. Apr 25, 2025SenateCommittee
    Reported back from conference committee, in place of, placed on calendar
  6. Apr 21, 2025HouseCommittee
    Conference committee appointed Hendrix Rohr Dobervich
  7. Apr 18, 2025SenateCommittee
    Conference committee appointed Lee Roers Hogan
  8. Apr 18, 2025Senate
    Refused to concur
  9. Apr 17, 2025Senate
    Returned to Senate (12)
  10. Apr 17, 2025HouseFloor
    Second reading, passed as amended, yeas 65 nays 27
  11. Apr 17, 2025HouseCommittee
    Amendment adopted, placed on calendar
  12. Apr 16, 2025HouseCommittee
    Reported back amended, do not pass, placed on calendar 7 6 0
  13. Apr 11, 2025HouseCommittee
    Committee Hearing 10:30
  14. Mar 26, 2025HouseCommittee
    Committee Hearing 03:00
  15. Mar 7, 2025HouseIntroduced
    Introduced, first reading, referred Human Services Committee
  16. Feb 25, 2025House
    Received from Senate
  17. Feb 24, 2025SenateFloor
    Second reading, passed, yeas 47 nays 0
  18. Feb 19, 2025SenateCommittee
    Reported back, do pass, place on calendar 15 1 0
  19. Feb 12, 2025Senate
    Rereferred to Appropriations
  20. Feb 12, 2025SenateCommittee
    Amendment adopted
  21. Feb 11, 2025SenateCommittee
    Reported back amended, do pass, amendment placed on calendar 6 0 0
  22. Feb 10, 2025SenateCommittee
    Committee Hearing 10:30
  23. Jan 27, 2025SenateIntroduced
    Introduced, first reading, referred Human Services Committee

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Sean ClearySenate · District 35RepublicanPrimary sponsor
Dick DeverSenate · District 32RepublicanCosponsor
Tim MathernSenate · District 11DemocraticCosponsor
Carrie McLeodHouseRepublicanCosponsor

Connected Entities

North Dakota board of pharmacy, North Dakota, seventieth legislative assembly and 2 more
OrganizationNorth Dakota board of pharmacy“Stakeholder consulted during the study.”Map →
locationNorth Dakota“Jurisdiction conducting the study and affected by the legislation.”Map →
Organizationseventieth legislative assembly“Body to which findings and recommendations must be reported.”Map →
Organizationdepartment of health and human services“Stakeholder consulted during the study.”Map →
Organizationinsurance department“Stakeholder consulted during the study.”Map →

Sources

Open source document

ndlegis.gov

Analysis Score

0–100
  • Significance45
    How much this matters to a regular citizen
  • Controversy15
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz20
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record